Fig 2: HORAS5 regulates the expression of AR target genes and has prognostic value in PCa. (A) mRNA expression of the labeled genes after siRNA‐mediated knockdown of HORAS5 in LNCaP cells. (B) Relative mRNA expression (qPCR) of KIAA0101 post‐HORAS5 knockdown in LNCaP and C4‐2 cells. (C) Relative mRNA expression (qPCR) of AR post‐HORAS5 knockdown in LNCaP and C4‐2 cells. (D) MTS cell proliferation assay in C4‐2 cells upon treatment with anti‐KIAA0101 siRNA (2 nm dose) or a control siRNA (5 nm dose). (E) Relative expression (qPCR) of AR mRNA in LNCaP treated with either HORAS5‐targeting or control siRNA (5 nm for 24 h), followed by treatment with the transcriptional inhibitor Actinomycin‐D (20 μm) for increasing durations. (F) postprostatectomy disease‐free survival based on HORAS5 expression [cBioportal, TCGA PCa database, 456 vs 35 (Elevated HORAS5) patients]. All qPCR results shown as data from at least two independent replicates, statistical analyses using one‐way ANOVA with Tukey's post‐test, ****P < 0.0001.

Fig 3: Immunohistochemical detection of ASPM (A), CDCA7 (B), KIAA0101(C) and SLC27A2 (D) protein levels in primary invasive breast tumors.